LENZ LENZ Therapeutics, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · Market cap: $129.8M
–
Bought and sold by quarter, last 5 years
Open-market purchases and sales by this company's insiders, in dollars, last 5 years
| Quarter | Bought | Sold |
|---|---|---|
| 2022-Q1 | $2.0M | $0 |
| 2022-Q2 | $1.8M | $0 |
| 2022-Q3 | $0 | $0 |
| 2022-Q4 | $0 | $0 |
| 2023-Q1 | $0 | $0 |
| 2023-Q2 | $0 | $0 |
| 2023-Q3 | $0 | $0 |
| 2023-Q4 | $0 | $0 |
| 2024-Q1 | $0 | $0 |
| 2024-Q2 | $551.0K | $0 |
| 2024-Q3 | $0 | $0 |
| 2024-Q4 | $0 | $0 |
| 2025-Q1 | $0 | $0 |
| 2025-Q2 | $0 | $26.4M |
| 2025-Q3 | $0 | $40.3M |
| 2025-Q4 | $289.3K | $261.0K |
| 2026-Q1 | $365.6K | $0 |
| 2026-Q2 | $0 | $0 |
| 2026-Q3 | $0 | $0 |
| 2026-Q4 | $0 | $9.1M |
Bought$7.2M16 buy days
Sold$76.0M14 sell days
Net insider flow-$68.8Mnet selling · 5 years
Latest trade2026-10-29RA Capital Healthcare Fund LP
| Date | Side | Insider | Role | Shares | Avg price | Value | Trades |
|---|---|---|---|---|---|---|---|
| 2026-10-29 | Sell | RA Capital Healthcare Fund LP | 10% owner | 2,718,684 | $3.36 | $9.1M | 3 |
| 2026-03-27 | Buy | Schimmelpennink Evert B. | CEO | 28,089 | $8.95 | $251.4K | 1 |
| 2026-03-27 | Buy | Chevallard Daniel R. | CFO | 7,500 | $8.57 | $64.3K | 1 |
| 2026-03-27 | Buy | George Jeffrey P. | Director | 5,592 | $8.92 | $49.9K | 1 |
| 2025-11-17 | Sell | Olsson Shawn | Other C-suite | 10,000 | $26.10 | $261.0K | 2 |
| 2025-11-07 | Buy | MCCOLLUM JAMES W | Director | 10,500 | $22.79 | $239.3K | 1 |
| 2025-11-07 | Buy | Chevallard Daniel R. | CFO | 2,198 | $22.76 | $50.0K | 2 |
| 2025-09-30 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 224,974 | $46.01 | $10.4M | 6 |
| 2025-09-18 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 135,304 | $42.23 | $5.7M | 6 |
| 2025-08-26 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 70,811 | $39.01 | $2.8M | 4 |
| 2025-08-25 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 78,237 | $39.55 | $3.1M | 4 |
| 2025-08-22 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 39,046 | $40.15 | $1.6M | 4 |
| 2025-08-18 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 45,713 | $38.56 | $1.8M | 2 |
| 2025-08-15 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 215,000 | $39.50 | $8.5M | 2 |
| 2025-07-10 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 191,376 | $34.00 | $6.5M | 1 |
| 2025-06-27 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 200,000 | $30.47 | $6.1M | 1 |
| 2025-06-20 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 234,801 | $30.29 | $7.1M | 2 |
| 2025-06-18 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 100,000 | $29.95 | $3.0M | 1 |
| 2025-06-10 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 350,000 | $29.00 | $10.2M | 1 |
| 2024-05-14 | Buy | Chevallard Daniel R. | CFO | 3,188 | $15.68 | $50.0K | 1 |
| 2024-05-13 | Buy | MCCOLLUM JAMES W | Director | 31,332 | $15.99 | $501.0K | 1 |
| 2022-04-12 | Buy | AKKARAJU SRINIVAS | 10% owner | 350,000 | $4.08 | $1.4M | 1 |
| 2022-04-11 | Buy | AKKARAJU SRINIVAS | 10% owner | 74,464 | $4.07 | $303.1K | 1 |
| 2022-04-11 | Buy | Gutry Phil | Other C-suite | 5,000 | $4.01 | $20.0K | 1 |
| 2022-01-24 | Buy | AKKARAJU SRINIVAS | 10% owner | 23,000 | $8.70 | $200.1K | 1 |
| 2022-01-21 | Buy | AKKARAJU SRINIVAS | 10% owner | 100,000 | $8.99 | $899.0K | 1 |
| 2022-01-20 | Buy | AKKARAJU SRINIVAS | 10% owner | 43,105 | $8.92 | $384.5K | 1 |
| 2022-01-19 | Buy | AKKARAJU SRINIVAS | 10% owner | 54,565 | $9.24 | $504.2K | 1 |
| 2021-12-15 | Buy | AKKARAJU SRINIVAS | 10% owner | 22,329 | $10.19 | $227.5K | 1 |
| 2021-11-22 | Buy | AKKARAJU SRINIVAS | 10% owner | 201,685 | $10.15 | $2.0M | 1 |
Who the insiders are, last 5 years
Everyone who bought or sold this company's shares on the open market in the last 5 years, biggest first.
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | 10% owner | $0 | $66.6M | 2025-09-30 |
| RA Capital Healthcare Fund LP | 10% owner | $0 | $9.1M | 2026-10-29 |
| AKKARAJU SRINIVAS | 10% owner | $6.0M | $0 | 2022-04-12 |
| MCCOLLUM JAMES W | Director | $740.3K | $0 | 2025-11-07 |
| Olsson Shawn | Other C-suite | $0 | $261.0K | 2025-11-17 |
| Schimmelpennink Evert B. | CEO | $251.4K | $0 | 2026-03-27 |
| Chevallard Daniel R. | CFO | $164.3K | $0 | 2026-03-27 |
| George Jeffrey P. | Director | $49.9K | $0 | 2026-03-27 |
| Gutry Phil | Other C-suite | $20.0K | $0 | 2022-04-11 |
Past buying clusters
A cluster is a run of purchases by three or more insiders. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
| Window | Insiders | Total | Score | 21 days vs benchmark | 63 days vs benchmark | 126 days vs benchmark | Status |
|---|---|---|---|---|---|---|---|
| 2026-03-27 | 3 | $365.6K | 57 | -10.3% (+0.6% raw) | -59.6% (-36.9% raw) | -71.4% (-57.1% raw) | closed |
| 2021-06-29 | 4 | $14.7M | 44 | -26.7% (-24.5% raw) | -40.0% (-39.1% raw) | -65.5% (-54.7% raw) | closed |
Yahoo Finance data, delayed, loaded through this server. Informational only; not investment advice.